- Home
- ARES vs TAK Comparison
ARES vs TAK Comparison
Compare ARES & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARES
- TAK
- Stock Information
- Founded
- ARES 1997
- TAK 1781
- Country
- ARES United States
- TAK Japan
- Employees
- ARES N/A
- TAK N/A
- Industry
- ARES Investment Managers
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- ARES Finance
- TAK Health Care
- Exchange
- ARES Nasdaq
- TAK Nasdaq
- Market Cap
- ARES 41.5B
- TAK 47.9B
- IPO Year
- ARES 2014
- TAK N/A
- Fundamental
- Price
- ARES $181.03
- TAK $15.52
- Analyst Decision
- ARES Buy
- TAK
- Analyst Count
- ARES 15
- TAK 0
- Target Price
- ARES $185.29
- TAK N/A
- AVG Volume (30 Days)
- ARES 1.3M
- TAK 5.1M
- Earning Date
- ARES 08-01-2025
- TAK 07-30-2025
- Dividend Yield
- ARES 2.47%
- TAK 3.50%
- EPS Growth
- ARES N/A
- TAK N/A
- EPS
- ARES 1.76
- TAK 0.59
- Revenue
- ARES $4,827,669,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- ARES $17.20
- TAK $0.47
- Revenue Next Year
- ARES $24.20
- TAK $0.80
- P/E Ratio
- ARES $103.24
- TAK $26.24
- Revenue Growth
- ARES 49.87
- TAK 1.52
- 52 Week Low
- ARES $110.63
- TAK $12.80
- 52 Week High
- ARES $200.49
- TAK $15.56
- Technical
- Relative Strength Index (RSI)
- ARES 46.11
- TAK 67.50
- Support Level
- ARES $175.94
- TAK $15.27
- Resistance Level
- ARES $195.26
- TAK $15.56
- Average True Range (ATR)
- ARES 4.95
- TAK 0.12
- MACD
- ARES -1.65
- TAK 0.14
- Stochastic Oscillator
- ARES 26.35
- TAK 96.72
About ARES Ares Management Corporation
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate & infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, & credit.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.